Actavis is a global leading player in the development, production and retail of high-quality general pharmaceuticals. The group is one of the five leading generic pharmaceutical companies in the world after the recent acquisition of the generic business of Alpharma (an American corporation). It has branches in over 30 countries across five continents and growing. Founded in 1956, its current headquarters is in Iceland. The wide manufacturing plants produce a variety of legal and safe drugs in different consumable or applicable formats such as capsules, tablets, injectables, sprays, suppositories, powders, steriles, semi solids and oral liquids. The group works on the production and marketing of high-quality generic pharmaceutical products for human use, conforming to good manufacturing practice (GMP) and covering all significant therapeutic classes (with expert and patent approvals)-Alimentary Tract and Metabolism, Blood and Blood Forming Organs, Cardiovascular System, Dermatologicals, Genito-Urinary System and Sex Hormones, Systemic Hormones, Systemic Anti-Infectives, Musculo-Skeletal System, Nervous System, Respiratory System, etc. Actavis has got one of the widest ranges in the generics sector with over 600 products available in the pharmaceutical market.
It is also presently in the process of developing another 200 different products.
Their simple policy is to provide its customers with a wide range of affordable, high quality, safe and reliable generic medicines. The Actavis group presently manages its flow of materials, information and products from suppliers to lab producers (and quality control) to final distribution such as wholesalers, retailers and healthcare via warehouses, ultimately to the consumers. This approach is known as supply chain management (SCM). 1 shows such an SCM model. It sometimes includes after-sales service and returns of bad and expired genetics for recycling or disposal.
SCM typically involves coordination of information and materials among multiple firms globally. Actavis drug products are of high quality but the company presently experiences the following SCM problems such as: (i) increasing trend towards production problems, (ii) recalls, disruption of operations, drug shortages, (iii) overstocking of products and not meeting distribution datelines, (iv) negative impact on new drug applications,
Please type your essay title, choose your document type, enter your email and we send you essay samples